On May 28, 2021, the United States Food and Drug Administration (FDA) granted accelerated approval to sotorasib for second-line or later treatment of patients with locally advanced or metastatic KRAS G12C mutant non–small cell lung cancer (NSCLC). Here, KRAS is linked to non-small cell lung carcinoma.